The main limitation of the present study is the limited number of samples; therefore an expansion of these studies to a larger cohort could confirm our findings and further demonstrate the utility of TTHY, RET4, PROF1, S10A9 and GDIR1, and NAMPT as biomarkers of LC onset in IPF patients. The gene discussed is NAMPT; the disease is idiopathic pulmonary fibrosis.